Mersana Therapeutics (NASDAQ:MRSN) announces positive preliminary data from the expansion portion of a Phase 1 clinical trial
evaluating antibody-drug conjugate (ADC) XMT-1536 in patients with
platinum-resistant ovarian cancer or treatment-experienced non-small
cell lung (NSCLC) adenocarcinoma patients.
In 20 evaluable ovarian cancer patients, the
objective response rate (ORR) was 35% (n=7/20), including two complete
responders. One patient showed an unconfirmed partial response. Eight
patients had stable cancer implying a disease control rate of 80%
(n=16/20).
The company says more data are needed to assess the antitumor activity in the lung cancer patients.
https://seekingalpha.com/news/3577849-mersanas-xmtminus-1536-shows-positive-action-in-ovarian-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.